Title of cohort

    H70

    Acronym for cohort

    H70

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Ingmar

    Name of Principal Investigator - Last name

    Skoog

    Address of institution -Institution

    Neuroscience and Physiology

    Address of institution - Street address

    Wallinsgatan 6

    Address of institution - City

    Molndal

    Address of institution - Postcode

    431 41

    Country

    Sweden

    Website
    Contact email
    Funding source

    VR, FORTE

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Neurodegenerative disease in general

    Q1b. When are studies on the above condition(s) expected to become possible?

    Already possible

    Q2a. In a single sentence what is the stated aim of the cohort?

    To study aging, health and health related conditions in older populations

    Q2b. What distinguishes this cohort from other population cohorts?

    The comprehensive examinations, long-follow-up and large time interval between first and last exam

    Q3a. i) Number of publications that involve use of your cohort to date

    700+

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    www.epinep.gu.se

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    38

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    108

    Q4b. Study criteria: what are the inclusion criteria?

    Birth dates certain years

    Q4c. Study criteria: what are the exclusion criteria?

    None

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    5,001-10,000 participants

    Q6a. Please describe what measures are used to characterise participants

    More than 1000 characteristics

    Q6b. Are there additional measures for participants with a clinical disorder?

    No

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    No

    If yes please specify

    Q7. What is the study design (select all that apply)?

    Longitudinal| Cross sectional survey| Prospective cohort| Retrospective cohort

    Q8. Are your cases matched by

    Other health assessment

    Q9a. Does your study include a specialised subset of control participants?

    Yes

    Q9b. If your study includes a specialised subset of control participants please describe

    Population cohort

    Q10a. i) Please enter the data collection start date

    09/01/1971

    Q10a. ii) Please enter the data collection end date

    09/01/2031

    Q10a. iii) Is data collection for this study

    At the planning stage| Data collection ongoing| Data analysis ongoing

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - intend to apply for funding

    Q11. Is data collected

    Through links to medical records

    Other please specify here

    Through study

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    Yes (participants given permission to be re-contacted via PIs)

    Q13a. Please give information on the format and availability of data stored in a database (1)

    Data summarised in database

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (2)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (3)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    Database on paper

    % available

    Other (please specify)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (1)

    Data is held as individual records

    % available

    Q13b. Please give information on the format and availability of data held as individual records (2)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    Data held on computer based records

    % available

    Q13b. Please give information on the format and availability of data held as individual records (4)

    No

    % available

    Please specify language used

    Swedish

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Apply to PI or co-ordinator at resource| Access through collaboration with PI only| National access|International access| Resource has own ethics approval so usually no need for separate external ethics approval

    Q15. What data sharing policy is specified as a condition of use?

    No requirement to make data publicly available

    Q16a. Are tissues/samples/DNA available to other groups?

    No

    Q16b i) If yes, please describe below:

    Living donors: blood| Living donors: blood derivatives| Living donors: DNA| Living donors: cerebro-spinal fluid

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

    Number of Patients

    4000

    % of total cohort

Types: Population Cohorts
Member States: Sweden
Diseases: Neurodegenerative disease in general
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF